ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.1650 (−82.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Adaptimmune Therapeutics PLC saw revenue fall 54.0% to $65.09M over the twelve months to Jun 30, 2025. Free cash flow was -$191.67M.
Revenue
$65.09M
-54.0% vs. a year earlier
Operating income
-$164.22M
TTM Q2 2025
Free cash flow
-$191.67M
TTM Q2 2025
EPS, diluted
-$0.11
TTM Q2 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2025
Valuation
- Market cap
- $55.46M
- P/E ratio
- –
- Price to sales
- 0.85
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -345.61%
Fundamentals
- Revenue
- $65.09M
- Net income
- -$169.76M
- EPS, diluted
- -$0.11
- Free cash flow
- -$191.67M
- Book value per share
- -$0.04
- Diluted shares
- 1.58B
Eleven years at a glance
Fiscal years 2013 to 2024 and trailing twelve months, USD
Revenue
$65.09M-54.0% YoY
Gross profit
–
Operating income
-$164.22M
Net income
-$169.76M
EPS, diluted
-$0.11
Free cash flow
-$191.67M
Reported periodTrailing twelve months